Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest CFO is former Bristol exec

Executive Summary

Forest names former Bristol VP-Finance Francis Perier as senior VP-finance & CFO. Forest's former CFO, John Eggers, will remain with the company, retaining the title of VP-finance. He was named CFO in January 1999 (1"The Pink Sheet" Jan. 4, 2000, In Brief)...

You may also be interested in...



Forest

VP-Europe Raymond Stafford will become president and exec VP-global marketing following the retirement of Exec VP Philip Satow Dec. 30. President and CEO Howard Solomon has been named chairman and will retain his position as CEO. Exec VP-Operations and Chief Financial Officer Kenneth Goodman will become President and Chief Operating Officer, VP-Treasurer John Eggers has been elected VP-Finance and Chief Financial Officer. Senior VP Lawrence Olanoff, MD, will become exec VP-scientific affairs

US FDA Races To List Essential Medicines For Domestic Manufacture By White House Deadline

With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?

ESMO: Pfizer's Lorbrena Makes Case To Claim ALK+ Lung Cancer CROWN

Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel